<Anchor> The

University of Oxford in the UK announced that 100% antibodies were formed in a vaccine clinical trial under development with pharmaceutical companies. Of course, this is the first clinical trial, but there is a long way to go, but it is a positive atmosphere. Overnight, American and German companies were reported to have succeeded in inducing an immune response.

This is reporter Kim Hye-young.

<Reporter> The

University of Oxford, UK, conducted a phase 1 clinical trial of the Corona 19 vaccine under development with the pharmaceutical company AstraZeneca, with 177 adult adults in the UK between the ages of 18 and 55. The results were positive.

A strong immune response has occurred in all clinical participants, that is, both antibodies and T cells have been formed.

The team explained that 90% of clinical participants succeeded in forming antibodies by neutralizing antibodies when the vaccine was administered once and the rest when administered twice.

[Andrew Pollard/Professor of Oxford University Research Group: We are seeing a good immune response, exactly the kind of immune response we expected. I think the results of this study will be a really important milestone in vaccine development.]

Researchers believe that the side effects of fever and headaches experienced by 70% of the medications can be managed by antipyretic analgesics. About 50,000 people, including 30,000, will participate in clinical trials.

US pharmaceutical company Pfizer and German biotechnology company Bioentech also said they succeeded in inducing an immune response in the second trial of the Corona 19 vaccine.

Earlier, US pharmaceutical company Modena also announced that antibodies were formed in all subjects in the first clinical trial, but it is expected that accurate evaluation will be possible only after the final clinical trial results confirming the safety and persistence of the vaccine.